Ontology highlight
ABSTRACT:
SUBMITTER: Holkova B
PROVIDER: S-EPMC4798896 | biostudies-literature | 2016
REPOSITORIES: biostudies-literature
Holkova Beata B Kmieciak Maciej M Bose Prithviraj P Yazbeck Victor Y VY Barr Paul M PM Tombes Mary Beth MB Shrader Ellen E Weir-Wiggins Caryn C Rollins April D AD Cebula Erin M EM Pierce Emily E Herr Megan M Sankala Heidi H Hogan Kevin T KT Wan Wen W Feng Changyong C Peterson Derick R DR Fisher Richard I RI Grant Steven S Friedberg Jonathan W JW
Leukemia & lymphoma 20151012 3
A phase 1 study with carfilzomib and vorinostat was conducted in 20 B-cell lymphoma patients. Vorinostat was given orally twice daily on days 1, 2, 3, 8, 9, 10, 15, 16, and 17 followed by carfilzomib (given as a 30-min infusion) on days 1, 2, 8, 9, 15, and 16. A treatment cycle was 28 days. Dose escalation initially followed a standard 3 + 3 design, but adapted a more conservative accrual rule following dose de-escalation. The maximum tolerated dose was 20 mg/m2 carfilzomib and 100 mg vorinostat ...[more]